Walter, Bernhard and Schrettenbrunner, I. and Vogelhuber, M. and Grassinger, J. and Bross, K. and Wilke, J. and Suedhoff, T. and Berand, A. and Wieland, W. F. and Rogenhofer, S. and Andreesen, R. and Reichle, A. (2012) Pioglitazone, etoricoxib, interferon-alpha, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial. MEDICAL ONCOLOGY, 29 (2). pp. 799-805. ISSN 1357-0560,
Full text not available from this repository. (Request a copy)Abstract
We enrolled 45 patients with metastatic renal cell carcinoma (RCC) at a progressive disease between March 2003 and April 2008 to assess the impact of an anti-inflammatory treatment regime in combination with metronomic low-dose chemotherapy. 42% of the patients had been systemically pre-treated. Therapy consisted of etoricoxib 60 mg daily plus pioglitazone 60 mg daily, day 1+, low-dose interferon-alpha 4.5 MU sc three times a week, week 1+ and low-dose capecitabine 1 g/m(2) twice daily orally for 14 days, every 3 weeks, day 1+, until disease progression. Objective response was observed in 35% of the patients (PR 27, CR 9%), which was paralleled by strong CRP decline for all patients with initially elevated CRP levels (n = 32). CRP values decreased from mean 42.3 mg/L (range 9.1-236), to 11.1 mg/L, (range 1.1-35.6), P = 0.006. Median overall survival and progression-free survival for the total cohort were 26.9 and 7.2 months for patients with elevated CRP 24.4 and 11.3 months (95% CI, 22.8-31.0/5.7-16.9) and 13.8-2.6 months (95% CI, 6.5-21.1/0.4-4.8) for the non-elevated CRP group, respectively (P = 0.082/0.017). Median observation time: 26.1 months; Overall survival at 5 years: 18%. Toxicity > WHO grade 3 was reported: Hand-foot syndrome in 16 patients (36%), diarrhea in 4, and pneumonia in 2 patients. Our data allow us to conclude that the control of tumor-associated inflammation is an important therapeutic principle in patients with metastatic RCC.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | C-REACTIVE PROTEIN; INFLAMMATORY RESPONSE; PPAR-GAMMA; CANCER; SURVIVAL; THERAPY; INTERLEUKIN-6; CHEMOTHERAPY; COMBINATION; TARGET; Metastatic renal cell carcinoma; Anti-inflammatory agents; Metronomic chemotherapy; C-reactive protein; Tumor microenvironment |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) Medicine > Lehrstuhl für Urologie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 13 May 2020 09:08 |
| Last Modified: | 13 May 2020 09:08 |
| URI: | https://pred.uni-regensburg.de/id/eprint/18705 |
Actions (login required)
 |
View Item |
